                         ˿µϣ20070728գ

07.07.28, ãйǴҽѧоõĵط
07.07.28, ΡԺԺʿѡĿؿעҺΪʲô2002
Է16˾Բȥˣ
07.07.28, bangbu1996ҽ
07.07.28, ķöѧλ
07.07.28, ¡ӷҽǱȻ
07.07.28, yuque2ҽ
07.07.28, ҫ⡶ɹڵһ಻ר
07.07.28, ٲ֮ѧ˭֮иС
07.07.28, йС𺣾Ȼ973ϯѧҡ
07.07.28, Ͽѧδڵ𣿡
07.07.28, ոͼĸлȻѧίලίԱ뱦Ժͨ
07.07.28, ƾ粨ϯ Ůʦƾ
07.07.28, ؤ֮ٽסҽѧøʲôΣ
07.07.28, ɽϴסȰ֢壬ʦ֧ͬԮĹϡ
07.07.28, й걨

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ãйǴҽѧоõĵط

ѧʱ 2007-7-27 ߣ

726Ѷ()724գԺʿϯ
廪ѧе2007ѧǰѧֻἰ컪ѧЭ
ᣬԿѧҵӢ˴һѧ棬Լо
ʼ20һֱ°Ѫƺоľ

ȻԿѧݽòɱ̸ҵҽƹ
ѡΪϰշӳǿҵʱǾͿ
жءһߴңȻս⣬йǽ
ҽѧоõĵط

ʩһʿǻѧЭϯ˹ٴѧϯڡ
ʩҲ廪ѧѧƸڡڽܳʱ˵Ǻܲͬ
һǣǺܺõĿѧңһλܺõҽһǺܶѧ
ġڣܶ˶ϣԼĿתΪٴƣ
ûиʵʩ²ˣз⣬֮Ϊо⣬
ֽоתΪƷдԵһϷһ
ǳεİѪΪйҵչ𵽷ǳĴٽáţڳ
쵼£йҵһµ㡣˪ưѪ
ķǳ÷ֵģֻڱ˷ֺ֮˻о

֮ΪйǽϴҽѧоõĵطΪ
й˿ڶֶӵдΧļõļ¼
ҽƱƶȲϷչƽ193535ӵ2005
72.9ꣻйĻ˼롢¼кܺõİԣҽҽ
ϡΪЩѵõĻᣬȻͬʱҲսȣ
һչָӻƣΣᱣƸ
ﲻơҽԴ̶ֲȲ⡢˲Ŷȱ㡢
оٴӦѽڵ⡣

̸йҵչĳɹýܣйԤͿ(CDC)
ѣѾ20036Ԫӵ200610ԪйͶ 7.3
Ԫĸ˼ذݿ⡪ȫ򸲸ǷΧʵʱ
̬ΪȫȾ͹ͻ¼ϵͳ

û̸Լйҽѧѧ＼չ˼Ϊһ
Ҫ᳹¡ؼԽչַ֧չδķչսԣ
ʵ֤ΪľˮƽȫҸ߼԰͸߼ҵĻ
ҵѧоϵ߲ͬоĿĺƣǿ
ʺҼίԱȵȡ

رǿҪ𲽼򻯻Чʣһװڲо
ⲿоڵйҽѧƣĹоԺ 
(NIH)򷨹ĹҽҽѧоԺ(INSERM)˵Ŀǰҽѧ
жȱƣ²Ҫظ͵ЧʣΪ
㡢˲Ŷȱʩϻ⣬´㣬о͹ҵ
ȱƣϵͺڿѧͼķչȡ

ΪȺڽ״ʵΪгͽС
Ҫ֡ҵо޴ķչռͶͳʾ2005
꣬йҵĲֵΪ800Ԫ2020꽫1750~2000Ԫ⽫
ٽõķչµľҵᡣͬʱȫҽƱϵ·
ͼ

ҽѧģʽת䣬ԤƸΪҪҸ֣ر
ҸĽ֡ҸγƵйġڣһ방֢Ԥ
ҸξͲԤ𣿡öĻѧ˵Ҫǵ֧
!仰ȫ

õı棬ζѧķѧҡﻯѧ
Ŀ(CUSBEA)ʼ˵һλʵϿҵˡţйҽ
ҵкܴĽչжôġʵμ˿
˴աеġ¼ר 

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ԺԺʿѡĿؿעҺΪʲô2002Է
16˾Բȥˣ

ҽ   2007725


2007527һλPbj11방֢йصվ
cancercompassд˶̶̵ļ仰ע⵽صģٴһʵ
Ѿɣ2003׼ٴʵ顣Ȼ󣬿ؾʹӵʧˡ˭
ܸйҩϢǲǻʵ飿һ˼
оĿ

Subject: RE: kanglaite
Date: 05/27/2007
I noticed that Phase I trials for this drug were completed and 
Phase II were approved in 2003, but then it seems to fall off the face 
of the earth.  Does anyone have current information about this chinese 
herbal drug and it's testing in the U.S. Interesting topic. 

Pbj11 
www.cancercompass.com

һ	ؿעҺûٴʵ
Ӣֽе׼޷ҵйؿؿעҺ
ٴʵκϢҺ׵ҵٴһʵļ
档޷ҵٴʵļ˹档ǣ1е˶
˵ؿעҺٴʵ׼2ؿעҺ
ٴʵûнлûɡ3Ҳٴʵ鿪
ʼļ¡

ǿع˾ҳӢĻõƬ֣
1	ٴһʵ顣John Hopkins University Ļ
ʵ顣
2	ڶٴʵ顣
3	ٴʵ涨ĳʵ顣ġ
4	йٴʵ顣

1	Phase I clinical trial in the us and basic studies of KLT in 
John Hopkins University.
2	Phase II clinical study in Russia.
3	Preliminary trial based on US phase II clinical trial protocol.
4	China phase III clinical trials.


John Hopkins University ѧĻʵ
20077201055֣ҴŦԼд绰John Hopkins 
UniversityѧĲEdward Gabrielsonҽ˵
ؿصĻоǷˮƽо

ҩƵĹ
ұҩоĹ˵һ飬Ȼй˶֪һ
ҩĳһо׶εĳɹеĹϵжһҩҪ
ʵʵ飬Թܡʵ顣ҩĳֿãԽ
ʱһҪͬеĲ룬ظʵ´ﵽ100ƪ·ֵ
òűΪģʵеĴɵġҽѧо׶Ρ
йǧҪΪˮƽоʾ߼оʵǡǡ෴1
еҽѧоǷˮƽоˮƽͨˮƽ2
ҩ֮󣬷ˮƽֵԽڸǻ򲢲֡ԣ
ˮƽԷּʹܱظҲҩĳɹúԶˮƽ
оǷǳолʮǧ

ˮƽоԺСоͨСʵٽд
ʵ顣ĸϵͳѪϵͳθϵͳȸӽӽࡣͨ
˴ʵſԽٴһʵ顣ʵɹˣҩ
Ск3-5ûµصĸñ֣ҩű϶
ȫҪʮʱʮԪ

ģҩоĹб̭ģ
ˮƽо̭ΪظʵҵԷֵС
ʵͲûЧ̫ˡСʵ̭90%ϵ
ͷҩ̭ԭҩã̫Сʵ޷ظ
ʵҵԽΪ֮ ʵǡġСǻ
ģһǼ򵥵ģһǸӵģһǵϵͳģһǶϵͳġС
ʵɹʵЧǴСĹϵҲֵĲͬ
ʵɹʵЧֵĹϵ˵⻷ͬ
ͷҲͬжûеġۡĿơ
ٴʵɹк󱻳Ϊٴʵǡ塱populationĴ
塣

ԣһҩкûб񶨣˵ɹˡſף
֮ǰоĵһ쵽еʮоУûһ׶ֵһ
Ϊ֮裬Ϊʱᱻ񶨡

壮ҽ˵̫
ͷйԿصı1993618գҹоȡ
ͻơҩƼעҺͨм199859գ
ҩоشͻƣֱɱϸͬʱ
ǿ߹ܣıҩΰֻиҩĴͳ۵㣬д˿ҩֻ
ܿڷʷ־ҩ̨ס 

ġٴݱѧ˼ӱĿȷܺ
鷽Ƚݷḻȫ棬Ѷȴɿ֤
Ϻ߼ǡɹΪҩƼִѧḻ¹պ
ͣΪҹҽҩشףﵽˮƽ
ɹٵȵȡ

ձơҽҩļ2002625ڳ飬ΰ


Ϊؼƽϳѧã¿Ժ
ʿǣ90ǵ׶ҩо̺ǣΪʲôװ
ң

ԺԺʿѡ᲻ؿעҺйѾ10
ˣôӦñ϶ˡסûκһҩֻй
ҩÿһõҩȫȫҩйһҩ
ϵĿѧҺҽѧҸȤֻйԼãһҩ
ΪʲôҪȥʵԭ򣬲

Ϊʲôٴһʵ˳
ٴһʵٴʵڶٴʵй
һзһзˮƽһһ½ʵɵʱǻƿЦ
һʵƻ20016µ20026ɡٴʵڶ2001
꿪ʼ¼1ٴʵй1995굽1997ꡣʱ⵹ˡ
е¶һֻйԺԺʿѡĿؿע
Һٴʵһ˳ȫƴա

ԣԺԺʿѡĿؿעҺΪ޷
ٴʵ飬Ż£ճһ֡ƭһƭ
˺ϰա

ͨ˶벻ףΪʲôؿעҺ16˵ٴһ
ʵ飬Ȼ󣨾˵׼ٴʵ飬ⲻǺܺõΪʲô
ʵܡأ

ҵһͣݱĨȥˡпƼóϢ
- йҽҩֵıʾ2003йҩֵΪ7
12Ԫ ... Iٴ黨ȥ700ԪԼһ£
ԿעҺ ...

ΪʲôٴʵҪڶ˹ְǰйٴʵ˵
ʵأΪʲôһطֻһǹܺǣԭǿؿ
עҺûЧûÿ֢Чһ˽һ¿ҩٴһ
ʵͶʵˡ

ߣҩٴһʵĿʲôָеĿҩ

ڿҩһٴʵǲƱ˺no harm 
ԭ
ĿǼ齨ļƳ̣ҩѧص㡣Ҫǹ۲춾áǣ
ԽԽоԱʼٴһʵй۲ˮƽЧ

1993NIHԺҰ֢ĵָļҩ
ʵ顷˵ٴһʵһνҩ塣ٴһʵҪ
۲ҩҩѧЧҩͨһʵͿԽʵ
顣ʵרŹ۲ҩĿЧҩر㣩
Чôһһʵ飬ҩǷЧǺϲʹ
ЧҲԽģʵ顣

ˣٴһʵĿʲô
վٴʵ顷clinicaltrials.govĹ˵¼2 ȫ
ģ20016£κǵHuntsmanоҽԺʼ
ؿעҺٴһʵ顣ʵĿ1ʵ
ϼ⿵ؿעҺܼͰȫԣָã
2ʵϼ⿵ؿעҺҩѧݡ3
⣨ֵܳģЧʵ鷽ǡꡱѭ򣬺עҩ
In June of 2001, the Phase I study of KLT commenced at the 
Huntsman Cancer Institute in Salt Lake City, Utah, with the objectives 
of 1) To determine the maximum tolerated dose (MTD) and the safety 
profile of KLT in patients with refractory solid tumors; 2) To 
determine the pharmacokinetics of KLT in patients with refractory 
solid tumors; and 3) To gather preliminary efficacy data. The method 
of testing is open-label, sequential cohort, dose-escalation study. 


ţٴһʵı
άҽ2003йؿٴһʵı棨ժҪ
ҽԺ˵绰Richard H WheelerάҽѾǶˡ

Phase I study of kanglaite (KLT) a botanical product based on 
traditional Chinese medicine. 
Sub-category:  Other Novel Agents  
Category:  Developmental Therapeutics - Molecular Therapeutics  
Meeting:  2003 ASCO Annual Meeting  
Abstract No: 990 ժҪ990
Citation: Proc Am Soc Clin Oncol 22: 2003 (abstr 990) ٴ
ѧ־200322
Author(s): R. H. Wheeler, L. Busby, W. Samlowski, R. Gerard, H. 
Farling; Huntsman Cancer Inst, Salt Lake City, UT; Huntsman Cancer Inst, 
Salt Lake City, UT, Albania; Kanglaite USA, Salt Lake City, UT ߣ
άҽ

ժҪ޲\ȡл񹲺͹Ѿ׼ΰ͸ΰ
ơйı׼Ϊÿ쾲2ˣ20쵽21졣Ѿ
ٴһʵԼʵ鸽ҩѧʵ
ÿ쾲ÿ21죬ÿ4ҩһΡǴһ1˿ʼ
ӵٶΪÿ1򡣷Ϊ4飬ÿ3ˣÿͬ4˽
ÿ3˵ơҩٶΪ1Сʱ1ˡ16124Ů
λ67꣬41굽80ꡣλPS706090вҩﶾ
ʵ顣ǵԭΪΰ3ˣʳ3ˣǰٰ2ˣƤ2ˣ
󳦰2ˣ఩1ˣٰ1ˣ״ٰ1ˣ֬1ˡʵ֤
в˶Կܺܺáûз2ѪҺѧ֢״Զԡڵһ
ƳУѿؼӴÿ5ҲûпƵĶԷӦˣ
ûȷܼһڵڶƳõÿ3ʱ˿
Ե3gultamylתøߣ2øߡûٴ֢״
Ƴֹ̺ͣơһڵһƳֹͣơԭ
Ǳûʱ䡣1615˿ҩﷴӦ5˼չ
10˵2Ƴвȶ104˲ȶ6¡԰
֬ҩʾAUC,CmaxмߣT1/2, Vdssм
Խ͹ϵйҩѧϸı档ǽһصٴʵ
԰Ѽߵÿ5ˡ
Abstract: KLT, an acetone extract of the coix seed (Coicis Semen 
Yokuinin), is approved in the Peoples Republic of China (PRC) for 
treatment of lung and hepatic cancers. The standard dose in the PRC is 
20,000 mg/day intravenously (iv) for 20-21 days. We have completed a 
phase I trial with pharmacokinetic (PK) analysis of KLT given iv daily 
for 21 consecutive days every 4 weeks in adults with refractory solid 
tumors. From an initial dose level of 10,000 mg/day, the dose was 
increased by 10,000 mg per day in each of four subsequent levels all 
infused at a rate of 10,000 mg/hr. Each dose level entered 3 patients 
(pts) (4 pts received 30,000 mg/day). 16 pts (12M/4F; median age 67 
yrs.(41-80) median PS 70% (60-90) were entered. All are evaluable for 
toxicity. Primary sites were lung (3 pts), esophagus (3), prostate (2), 
mesothelioma (2), colon (2), carcinoid, pancreas, thyroid, and 
liposarcoma. KLT has been well tolerated with no Grade 2 or greater 
hematologic or symptomatic toxicities. No dose limiting toxicities 
were observed in the first cycle up to the maximum dose of 50,000 
mg/day. A maximum tolerated dose (MTD) could not be defined. One pt at 
the 30,000-mg/day dose level experienced reversable, asymptomatic 
grade III elevation of gamma glutamyl transferase and grade II 
elevation of alkaline phosphatase during a second cycle. Three pts 
stopped treatment after two cycles and one during the first cycle due 
to the time commitment required. Of 15 pts evaluable for response, 5 
had progressive disease, and 10 had stable disease for at least 2 
cycles with 4 pts stable for over six months. PK analysis of the 
target fatty acids in KLT showed a dose dependent increase in AUC, and 
Cmax, with a decrease in T1/2 and Vdss. Full PK studies will be 
presented. The dose recommended for further studies is 50,000 mg/day. 


ʮҩٴʵĿʲôָеĿҩ
ԺҰ֢ĵָļָģʵ
רŹ۲ҩĿЧһҵƪ¡ôҶԺͷ
һĸ
һĿҩٴʵ򡣣ԭǷģ
New trends in assessment in anticancer treatments by phase II 
clinical trials
[Article in French]
Medioni JR, Rycke YD, Asselain B.
Unit de biostatistique, Institut Curie, 26, rue d'Ulm, 75248 
Paris Cedex 05.

ѧٴʵµû㹻ԣĿЧ
Դһʵ顣ٴʵһµĿƵķչǹؼһ
ĿǽƳ̣۲ռָ꣬ķӦ
ϢͨҪĹ۲ռָСЩоԱ۲μռָ꣬
ʱƵĶԡ
The aim of phase II clinical trials in oncology is to judge if a 
new treatment have a sufficient antitumor activity to justify further 
studies. They represent a crucial step in a new anticancer therapy 
development. The aim is to present phase II clinical trials 
planification and interpretation methods, end points, recent methods 
and news in tumor response assessment. Changes of the place of phase 
II clinical trials in a new treatment development strategies are 
finally shown. Non randomized trials planification methods (unique 
analysis, Gehan's method, Simon's procedure, Fleming's multi-stages 
procedure, triangular test) are described. Usual primary end point is 
tumor size diminution. Some studies are interested in secondary end 
points like survival data or treatment toxicity. 


1998һƪ¡ĿҩٴһںͶʵ
ռָ꣬ЧԺʵԡ
Ann Oncol. 1998 Oct;9(10):1047-52.  
Phase I and II trials of novel anti-cancer agents: endpoints, 
efficacy and existentialism. The Michel Clavel Lecture, held at the 
10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 
16-19 June 1998.

СĿҩٴһڽͿʼЧԡ
ٴʵĿľΪҵҩǱڵư֢Чͳķ
֯涨ı׼СҪἰ
ҪһǣҩķӦζЧǣЧζʣ
ʵСΪʵռָ걻֤Ƿǳ
ġʵСʵ԰ѡҩƳ̣۲ҩӳ
Ч
After phase I: Screening for efficacy
The goal of phase II trials is to screen agents for their 
potential for efficacy. Traditionally this has been measured by 
objective tumor regression described using standard criteria (e.g., 
World Health Organization). It is important to point out that response 
per se is not synonymous with efficacy; rather, efficacy means 
improved cure rates, survival or quality of life. Tumor shrinkage has 
proved to be useful as a phase II endpoint because it has allowed us 
to select drugs or regimens which have subsequently been shown to be 
effective by prolonging survival. 


ʮһ˭ҵءֱɱϸ֤ݣ
ݴҶһ£ԭٴһʵǲҩĶ
ãͨһʵʹﵽˡͷˮƽԶٶ
ʵҪˡҩܼСͷ˶ʵ
顣Ϊΰ֢Ч

йĿѧĵ˵ֱɱϸ
ûа취ҵκһʵ֤ʵܹСȫֻ
һ˵Сϣܹ˵ԭʼ
档ĺ¼534ûһоṩС֤ݣУܱ
ظй60˴Ϊһ˿أʮ֮һ6 
˳СôԲƽ¥Աߵ
ƽգһǧȵĽҲܿ¥οҪٴһʵ
16ˡôٵĲͳѧŴ󾵾ǿҲкܴ
ԣһҽѧоѵ˿ĸ¼Ĵ534Ŀͽۣ
ж˿Ч嶼ˣ㻹Ҫоʲôѵ
¼534ûзСҺǡǡ෴
Ϊ¼534 ˵ѾǺۣܰæ
ˡʱ֤ܡ˵ͲʵѾθߡ
ˡ

ʮԺԺʿѡƭ
ٴһʵĽһʵĿȫǺϡɵ1û˶
ĶٴڡʵöĻӢдԭʼ档Ƿǳ
µ¡2й1995굽1997νٴڡʵ顣
2001ͬʱڶʼڡʵʼһʵ顣һ
Ŀһڵʱ򲢲δ֪£֪
չġ֪һʵҪļƳ̿ͨΪʱ
20˴κ͡ڡʵѾ֤˿ûо綾ͬ
׼ٴʵ£Ҳ֪ߵġΪ
زܼСʵ綼֪صĿǰΪֹǸͷ
5ڲܶˣûСձ˵ġֱɱϸ
á

ʮǿ߹ܡҩͨ
ԽԼʱҪ˵˵Լġúسǻ
Χ˵ԼѧʵֻС˵
ҽǡѧеҩǿ߹ܡڡ
ձ˵ġǿ߹ܡãǿصġس
2003ǵʱõİ֢˺Ͱ̲õвҩȵȶ˵ǿ
߹ܡͳͳǷŹƨ

ʮġж壿
Ϊʲôеҩư֢ڵĲˣΪʲôЧ
ƷԼƺþЧҽҴĺֶΡò˵ı
ѣûң˵ڸҩЧҽ˵ʱ׼С1
С2Чζʣʱ򣬶
ͿԿЧҽ档Ϊ϶
ϣֻҪ˵õ˾Чϡôҽһ޴

ʱ׼ĸʻУСһָ꣬ҲСӲָꡱhard 
dataʣǶָꡣرǡָ
ꡱsoft dataκһ˶ͬʱ۲ĸָģرҪ
Ӳָϡȫ۲ź߼ǲҲͺ
˵ȥһﳤƯҽ˵ֻҪ۾Ư㳤Ư
ͷֻһߣȥѡ

ʮ塣ҽйäĿҩʵʱֹͣ
ڰ֢ˣйҽֻǳ̶Ⱥͷ
ܴͬϸضԲ޶ԭԵй׼20
˿أŻͬٴһʵ18ˡΪ
ļ20˴û򶾸ͣ˵ûо綾
Ȼй20Ѻͬ⿪ʼĵһˡ
һעϥؽڵҩhyalganŷٴ5-6
áҽͨ˶֪áôʣй
ģйע俵صʱʲôġѺ
ʵ飬ȴйÿص60˴Ρ˵ʲôй
ҪҩһҪԳ漣Ҫйϰһ仰
˭Ҫ

ʮҽʱûҪ˵
ҽ˵ȫ綼ƳҽҩҿǺԽԽ˶ҩо
ȤרѯҵһҩMerckоĻѡ˵
ȻֲڵĻ˹ܺϳɵĶˡˣвҩҲһ
оĶһѰ»ԴؼǣΪֹûпһ
ҩҩעоһҲûС˵⣬
1ǰ˵оҩѡǡʮĥһ2ΪѰ
ҩĶԴвҩȡݡĳɹʸߡԣǴ󿴣
10꣬20꣬30꣬ҽԽоҩĹ㷺ԣʱԽ
Խǳճɹǽ׶γɹҩԽûáĽۣв
ҩͲһġ

ҽľ˵ѡҽ˵˭˭ʼоҩΪʲô1
꣬2꣬3׷ٱ1꣬2꣬3оĽʲôΪʲô˵Ը
оҩպý֮仹ʮǧ˶֪о
ֻǿʼ ˽ ҽʱΪʲôѡԸоҩ
󵼳ɡⶼҩáַʮֱӡ

Ǿͽҽһ2007724աˡ
ٴ2009 ע⣬йѾ5ˡ
2009ٴʵʧˣ۳ɹ
2009һᱨ

ʮߡձþʱû˼
1958ʱձܻ200381աձ
оͰԼеݸĨˡûз
СձΪʲôӢǸʡձ
ǽĿصʱ򣬵ر֤ΰЧʱ
й񿴵ļ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ҽ

ߣbangbu1996

ʱġϡǸıϧԱĽȴ׾Ӷ޳ܡ

ҽƤ֪ĺûҽпƤȻҲ֪˺
ȴƻϵġԡҽ۱ҽĻԭ۸
ҽĽ͡

ֽ©ٳ˿ڵʡʻڡġõж
֪ȷģҪСԱȶԱҽûУ
ҽпֻеֲ̫ڼԭʼе˻ɫä
ϣǲõǲȡʯͷ֮ġС硶ҽָĴ
Ūʬ巨ȻɾҽΰĽʷ֣ҽ˵
ģ˵Уڵзʵòֻ֣ýƱ˵Ĳǡ
ԿѧһƱ磬ĪʹҽѧԽУ
塱ٺ٣

ҽأʵҲǴӼ򵥵еĹģ̥ˡй
Ȼз޾ġĲϵġСڡСо
ףġгҲ׼ȷҽġСķȻ
壻ҽġӴߵᡱķͬƻ壬ȴˡС
ںǷġͻ˳ҽN
ڲϢȻϱ˽ԵҪӺֹ򱶣
ġķȻȱݡЩϲҲĲģʱ
ҽͽִƼģ䲻Щ˺壬Ϊ˲ϻҲ
ֻȡˡҽأһΪСķɫƾ
˼ĳһϲһּ棬ӲͦŲִ
ֲֶҽļҵҽǿãȻȻ˭ˣ
Ȼ⣬ִƼֻϸDNAȴ
ʲôӪнҲֻСܡûʵ
ĵӡһҽΣһҽСҽ
ִɣ൱߶ֺá

ҽ˵ˣĺвĿģҪȥǣҽĵٲѧ
ҲԵùҽٿѧһζȻģ
в˵ߡҽԵĹϣû죬ΪҲװųԵ
˿ٺ٣ҰģƤһƲ𻹴󲹡
֮ҽԵĹһҪǹϲл廹ܻҽ
߼ҽأһƬƬţԵװܲ𣿶ҹӶͦ鷳
ģҽŴƷأٺ١

֮ϣҽеóףĵ׼ȷҽҲУĻǺ
ƣҽеΣĵúͿˡ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

öѧλ

ߣķ

йִѧƵѧλѶʿѹĿõģΪѹ
ɱҲ˵ƴѧСйУ˶ʿ
ʿڴƶȸ£ʦΨͼæӦ꣬Լ
֣ҪǰʱóҪĽ˶֪·
ѡҪĪΪ潡ҪĪʡ

ִƶȶЩʾǼٵѧУѧλ˵ٳɼ
Щ˶ʿκѹ˭˵ҽʿѹɱģΪ
ҶνĿ⣬ⶼǼٵܳʲĪأֻһ
֮ٵļ١ټĳЩƴѧҽרҵ˶ʿƷ

ƽǱSHRѪƽϸCaL-1CPMCA mRNAӰ졷
ͬҩȡСɻûƵıȽо
ҩаͽѪЧɷо

Цһִͳҩ˪ĳƴѧĳЩ⿹
飻и๹˼ԼΪ

軯ϸӰ졷ߡҩP53áй
ϵĻСŪȻѧĿٴġ

ȫϴѧƼ۵ѧУҽҩѧĪߴ
Ǳҽҩѧͳɶҽҩѧˡ˶Ⱥ죡
ȻЩĴѧҲ󣬷׷ҽרҵѧλ㣬
òʿƾֲԸѹĿǣٳɹûĵʦǣҽ
·Σ

ͳҽΣ޵ģıƷϺҽҩѧԣ
֮࣬Σȴ޵ġǵͽѹ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ӷҽǱȻ

ߣ

³ѸŴҶò٣Ĳ˵Сѧѧϰ
Ŀαûһٵ³Ѹµģ³ѸҲǱȽϳݣڹٷ³Ѹ
Ҳð˵ˣڱȽĶ϶³Ѹ
ί³Ѹҽģ˵ԼϤΡ
ˣʱȽźоվ˹

Ӵ˿ͲҲڷҽ룬ⷽĳѧ
³ѸҲͰˣô³ѸĴҲһѧأİ
߱£ʤΩҽðΪһ
ѺͬǱȽźоվ˹

˿ʱ䳤ˣ𽥵ؽ˷ҽһЩ۵㣬Ȱ
ҽҳЩʲӵĲҩĳЩҽĴˡ

Ҳ˼ǰһ¡ɩУ·ݺܴʱ
ð˵иҩ̥ã͵ĳҽȥ˼ҩ
Ҫҩް֣гҩܲң̥ڸزˣΪ
ǼĳӣԵʱ嶼ǳˣʶڱ
֤иȫ֮ҪҪ̥ԭԺٻл
ͬջûв鵽ԭ֮ϲɩϲ
ùӣҺӷǳϸϸʱȫɩӶչмӣ
һ©ΨһпܳĵطǼθðҩҲҽ
ѧרҵʿԲҶ϶ҽǣЩɷݲ
òҩ׾Ϳиʵ̫Σ

ҩװ˵϶עиûиãͨ˲
ҩиȫĴԼ˼ꡣһܶͨϰ
ıҾҲǷӷҽĵڡ

ҽ϶һֿѧһĻǳ춼ĻѬ֮
УǽܹҽѧרҵߵȽ˭֪ҽԭһ
ƭӡϲܶѶȵǡһҩ
ϲܶҩɵģϲС˵ӹ
ʾ˵ҲҽľͼϲӾ磬ơҽϲ֡
ĽĿչֵȫҽ棻ũϼҵĸǶƶ¸
ƶĿǡֲҩġ壬ҽֻ
ҽһӣҪҽ
һȣ

ӵȻɣһһʱỹǽܲˣ
Ϊǿʶ

磬˵ҽЧãĳҾǳҩĳĳҵĳݻ
ĳҽû취ҽһ¾͸κˡ

˵Ҳ˵⣬ܶಡξͻõġ

ˡĻشǺϽܿѧģûܹרҵѵ
Ǳ׼ĺǿʶĻҲȫȥˣͷ
һپ൱ˡ

أΪӷҽġǱȻġǧ˼άҪ
ȥıǲһһϦ飬Ҫעۣⷽ
˶Ȥֳڶ˿ģ渵Чá

ҽĴ߻ǴǿƵλ˯ϲCCTV4и
лҽҩĿһҽXXXӾĸ޿ѧϽԣ
ʲôԱҽӣʲôҽʲôѧӻ
ԾҽרҵΪһѺΪһѺ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ҽ

yuque2
http://blog.sina.com.cn/u/4de90978010009qy

Ĵ,ǻʲô?ûʲô.㿴Χж
,Сƿ,󵽷ɻ,Ǳ˷ô?νĴ
ͱûڷĺ.Ѱ,,ǶĹ׺һ
ĵλʵ̫,Щ߻ڷؽ,ʲô
ý?һֵĸʼ,ǹĸ,Ǽĸ,ʵϸһֱ
ڽ,ֻи߳͵ͳְ֮,ͳʱԾı仯,߳ʱǲ
֮Ϊ.ǰǱչ,üᴬڴǵĴ,ǵ
ΪǵҹԴ;ǿ,,̫ľɹ˼ά
,ǲΪ,ΪЩµİʯסǰ
Ų.

ſѧ,ͲҪѧ.ѧҪʵ˵,ʱ,ѧ
ʵ!ҽ,ȷе˵ҽ,ѧ,Ļ
,ʲô,ʲô׾,ǻ?ڵҽҪȥ֤Ĵ
,ΪʲôҪȥ֤?Ҳ˵ʱǲڵ,ֻΪ
ܹԲ˵׫,,ȥ֤,ҪôԱҴ,Ҫô
.

л,ȻҲΪе۶ȷ,Ծɷǳ
л,Ϊſѧ,ۺͼӽѧ!,
ѵıȽһ,ûһ,ŬѸ,Щ
е,ںһײǽյĴ,е˲ȡν̬,
˯,е˷㳳ǵ,Ҫ"һ".
̬Һܾ,ҲܹߵȽ,ûĵʶ,֪ʶͼʶ,
Ҳһ,һ,ֻһС.Ҳܱ
֤ԶĲ,ΪѧҵԪ˧,ֻ߸Ӵѧʱ
ҲŻҳ!

ȷһҶҽ̬,޳ɷ"ҽҩ"ᷨ,
ڲִҽѧ˵,ҽǺǳ,ǧ˻ҪŪЩ˻Ƶ
ν "ҽ",ǿֿЦ,ô,ôչ?ٸ򵥵
Ӱ,ԭڵһҽҩҵȡϳһԭҩһ㶼Ҫʮ,
ʮ,Աߵһҽҩҵȡһҩһ㶼һ,֮ļ
ɼһ.ʵҽ̬,г־õ֤,ҽԺ
ڸҽ,ҽѧԺҵҲڴҽҩ.г,
ѧͻͽʱҲҽʦǽݵʱ˰!

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ɹڵһ಻ר

ߣҫ⣨һũֲˣ

רƣ಻ƱרţCN200410022738.4
CN1706368  2005.12.14 ˣĴ½Ƽ޹˾
ˣ棬

ݣһ಻ڿԻѧڣ
3- -1.2-Ϊԭҩռ0.51ռ99.599
Ƴɿ״ԲĶϼΪ׷1020 10
20Ƥ40 601020ʳ1 5ֲ1һʩҩ
ܶȿڲΣˮƽ£Ϊ15£Ӷ󺦵Ŀӳ
һαΪһһλΣʡ˴ҩȫɿ
Լݡ࣬ԣжȾ޹ϻҪ
ɹ㷺Ӧڼͥũԭȴ

ɣ1ԭҩ 3--1.2 - ӢΪ3-chloropropan-1,2-diol
ı3-ȴ,-ȴ,-ȸ ,ǡҩǹ70
ڱעĲƷҹ70ҲһЩоΪ21
ͳڹ걨רԺʿμӵļͨ

2ҩȣжﵽ1%, ͨҩ
200-40ôߵǶɱǲɱôߵܲȾ
ͶǰжΣ

3ʵӦõļֵо治ɱ֪֦꣬-
ֻдʹòʹֳָܺܿԣ
ÿ࣬ҩˣʹóɱܸߣг
ҲΪʲôע30꣬ûʵγӦõҪԭ򡣱רһ
ҩЧ15 £һЩͬ鲻һ¡̴༤ز
ȿǵĲܵͣǺͨʳеķֳ
ƻ̬ƽ⣬ڹûеõӦõԭ֮ۺ
ϷǳɹڴӦõ̫࣬Ŀǰֻʹ
õӦá

4ڵһЩɱ飬ȱ۵ͨҩɱձȽϣͱ
ͨҩɱֿɱЧ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ѧ˭֮и

ߣٲ֮

˷ġѧ˭֮зĺ֮飬
ȷĿǰѧ٣ʦĹѧ

ѧкǿѹΪĿǰ˶ʿ͵ĵʦ
һĿͷÿӦ꣬㣬û˼Ҳûʱоѧʣ
ѧνĿ걨飬ȥɼ·ҪɵĲ衪
סȥȥʦͻ᲻ģʦһģѧ
ѹͱóʺϻ걨Ľķʽ϶걨
ȷ

ѧʵ˵ʦļ·ߴˣΪʲôʦ
أΪ˵걨ˣ˵ʦˣͲܽ⣬Ӱ
ʦһ𣬡⽫µʦĿȵļ䣬
Ȼǵʦ޷ܵġ

ѧռȶ"·"м"ʵ"
ʦˣ˵Ľѧڻ޷ҵһıָ
£ھáѧҵѹǰкܶɹӣ˵Ĵ
ΧСᡢûᾭѧҵѧ
"Ȫ֮ˮ"Ϊɱ̫ߣ2426ѧϰ̺壬
ҵܼѣûһͬ飬ֻᱻ˳Ц

ʦأʵҲΣ빹ġԭԵĽ
ǿҿԵļ·ߣǣЩʵ֮ǰó100ȷ
ͽۣǻпС̽𣿵Ŀ֮ǵĻ
ǲʧܵģ֧걨ݵķĿ´֮"
ͬ"ɺͬԺҪоûţ˵ʦϣԼ
ÿ""ʵĸѧǣͲˣ˵ķʽ
ѧѧߣƩȳԺʿѧ֮£Ժʿ
˵"ƻ˵ҳʲô"ǰһҷĵʦ
һǱΪ潵ģͨҵĳϴƵɣ
ƵѧǿƵĵʦҲΨһķɣ֪ǣ
ԺʿǷ񿿻ͬѧĽĳشĿӻһ
ĿıӣٵĽǷӰĿۣԺʿ"
ò׷"ѧǷɽ賴"ж"ĿʧܵΣ 

Ļ£ʦѿ͹۵Լļ裬ǣٵʧ
СΪǴӸ̶ѧٵ"Ҹ"ҿжθ
ѧĻɱ֮СԼĳɱ˾޴ǵ
ʦѡ

ԣҾ׷˷ԴԴͷ⣬Դͷ¶棺

һǲһĿ걨ʱ򣬾֪ȷļ·
ߣǣҪʲôĿĿ飿

ڶǷһĿһҪõԤڵĽ⣻֤ĳ
sound·вͨģǲҲԽ⣬һȽϺõġŵġ
Ӱ´걨ۣ

ѵ룬ǲǹ͸һ㣬ҸĻᣬ
ἯϣɷÿרԱڡ
3ꡢ5ʱڲͬʵľѣԱԱͬʱͬʱ
˶ԱⳡĲԱǳ˶Աⳡ˶ԱǳĲ
Ա˴ء

ģѵĹϣǷСĿһ㣬ùһ㣬ز
ŲٸݾѵĲӦĴ

壬ѵʹϣǷҪϸƣ100ľˣֻҪ
ܱ½ˣҪʵҪҪ100
ֻĿȥԼı˽

ְơôǷҪ;ѹô뾭ѵʱ뵽
Σ棻е룬֮֮
Ψֲ


Ǹˣ⣬ܼһ롣һ˵滰
Ҫܸߵĳɱʧȥıϣܵĳͷɱ˳еķΧ
ĺ͵µ̫Сˣ˵ڶ㣬ƻỺͺܶʦϵ
ƩԺʿͲڹؼʱͱԼѧһȫԼˡ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

𺣾Ȼ973ϯѧ

    ʵҵҳһϢ˸е
Ծ˿ĻпƴĽͬѧȻѾΪ973ѧҡ
֪ҵĿвôģΪʲôشĿѧϽ
ںͿѧȥ

йС

𺣽ǣͷġϵͳ⻯뷽оѡ2007973ƻĿ 
2007-7-12
  


    79գӿƼھٿġ2007973ƻĿ֯ʵʩ顱ϴϢϵ 
ͳ⻯뷽оѡ2007973ƻʵν𺣽ϯѧҡĿ 
ð˸ӿ;оŶɻпƼѧѧ廪ѧϺͨѧƼѧ㽭 
ѧϼ㼼оƹŵڶоԺɣУĿ걨λ 

    ĿΧؼѧоϵͳ⻯ģʽ1ϵͳĶ̬Ϊ 
ϵͳϵṹĽԴʹ֮ìܣϵͳṹĽǶȣӦ 
󣬽ԴйͶ̬֣Ա㶯̬ڶ˵߻ڷֲʽԴ 
㻷2ԴʹõĸЧ͸ΪϵͳԴĸִеĸЧ 
͸֮ìܣӼԴ֯͹ĽǶȣ칹Ӳ豸ӵԼ 
ԴĹ㷺ֲԣʹϵͳָЧʡ͸תʽ3㻷ЭͬʣΪ 
ϵͳʹûĸӦõĸԻ֮ìܣûʹûĽǶ,ֲ 
ع趨ƵĿӻûʹûͳִеԶûӦӲ 
仯ЭֲֵļԴִеЭͬ㻷 

    Ŀĳɹ걨ʵҵоˮƽǿʵڼϵṹ۷ 
ʵ棬ͬʱʵѧУܲźѧԺ쵼ָ֧,עԭ 
оѾЧ˻۳ɹۺоʵ,Ϊ̨׵춨˻ 

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

Ͽѧδڵ



  ǰϿѧδڱΪԺʿѡʱһƪԶ
¶֪ѡǲйءǵõʱεѧֱ׳ر˵ԼӢ
ˮƽãǽ˹оԱеһʵǡ
áģʵҲΪǱǰ˷Ķδھ
ôҽһôˣйءż𣿴
ѧϹ˴ͻǰǵĺͬ־ôֳĬһ㶼

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ĸлȻѧίලίԱ뱦Ժͨ

ոͼ

, ලίԱ򱨡 (20071)ϰݶ˼ලίԱ
ʦѧԺԺ뱦걨ʱٵͨ. ĸлȻ
ѧίලίԱ뱦ƭΥΪͨľ޴ٶ!Ȼ
ͨЩ(2005绰ٱ, 20067ºٱ! 2006118
վϽ¶), Ҿ,Զѧپлƶ! 

ڡͨĳĳڶԿѧĿ涨Ͱ취˽
ȫ,˴. ѵ뱦ԺĶԿѧĿ涨Ͱ취˽
ȫ? ڹȻѧ ߳ŵȷ ұ֤
ݵʵԡ.ʧʵΥ涨,˽еȫ.  
μ(7)뱦Ժǩֵ. ΪˡĿҪԱŵ
ʵ?! ѵ뱦Ժû⡰ŵ?

Ը뱦ԺԺҪ١ڶ塱!

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ƾ粨ϯ Ůʦƾ

 ǵ>>ό>>2007-07-25

ǵѶѧ2008˫չܼ࣬ļٲ
ʿݱع⣻KBS̨ˡϺãPopsĿӢｲʦ
ӢҲϱ˹ѧѧʿ˶ʿѧ

ݡοѧվŷڳ
Ү³ѧʷϵʿѧλɣѧҮ³ѧȷ
ģҮ³ѧУĻظĵʼʾĲʿѧλǼٵġ
˫չίҲܼʸ

35ǺͷΪ˳
˲š˴ƾٱعԺѧĳ֪
ͬʱKBS̨ӢʵֻиƾӢڼ
ԼҵӢٴѧѧ˶ʿ2000걻ѡΪ KBS̨
ӢĿϺãPopsˣܻӭ

Ӣ˼ð˶ʿѧλһ£ȥKBS̨Ĺ˵
1990ǰӢλ׶ضϲСлѧԺѧϰһ꣬˺
ֵڼרҵѧУѧϰһꡣʵûϹѧ

20063²ýǮڶ˹ִѧü˶ʿͼٲ
ʿѧλһٶʮˡн֧ǧԪ˼ѧλʵ
ͣڶ˹ʱֻҡЩвдѧʦн
ڣǻˡ˹Эᡱ

ձָĿǰں䣬ġƭ
ŴڡֻҪѧ֤Ƹ˼ʹϵƾһں
ϡԵÿ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

ؤ֮ٽסҽѧøʲôΣ 

ֲˣԴϷ

¹֮׷١Ϸ細ɱؤժȡٵĲҰ
ֱӦԴ˰ֱӻε人ͬҽԺ永ҽûܵ
׷Ҳûбֳϵķʡ԰һ޹ؽҪĸְӦ
¡˵ķﱳӳйгĻңҽѧ̰ʹ
µݣ߷ɵĲȫ

2007715ճġϷ細־ϱһŵĲҰﷸ
ͬӣؤڸͨҽ½ϵ人ͬ
ҽԺƭҽǸձ̵ִ佫ࡢժȡ
߿1.48Ԫ

ҰıѱýתأΪȷŵʵԣߴ
绰Ϸ細־磬µα༭ʾƪȷʵǷġ
Էͬıͷ̣˵ú
ʵǶڳ䵱ϵˡɫҽ½ܣֽǰȡ人
ͬҽԺҽºӦܵķ׷͵Ǵ𣬲
ûиۡ

ɱ˵ٵȻɥﲻ⣬йҽѧ
ֲôй߷©гǷǮ׵
ڣﷸҲ޴֣ΪϷֵѰԴϢ

ǸݡϷ細ıͼ߶෽˽永ҽûб׷
Σֻ֤˵ݳ֤ͥº󣬲ժȡٵ人ͬҽ
ԺֲоĽҽҽִգԭλ
֪ˮΪ쵼αְ˵Ҳǳ䵱򣩣Т
ƽΪ£Ķʦڡƽ̩Ѿ94
пԺԺʿ÷涯ԼĹϵԴ
űסɴûб׷쵼Ρ

ϵԴҽ½ܣ˵人ͬҽԺֲо
ʿоܵʲôͲö֪ΪṩϢ
Ҳ֪˾ʲôλǾרŴԴġн顱


永ҽƻ人ͬҽѧԺͬҽԺֲоǹ
ֲĶֲɹʤö١ٵ
֮ǲԶġ֪ʿ͸¶γֵĲҰ
żȻΪгһֱڻҵ״̬Ȼɷȷֹ
ٵҽԺһִвϵ̷ʬȡ
£нǮ׻ǸôѵҲǴڵġ

Ȼҽǰ֪ҪժٵĲ̷Ǹ޹ɱ
ؤԿ϶ȷʵһŹߺֽ·ġ
˵ҽѧԴĲԺͽǮ׵ȷʵڡҡϷ細
лһϸڣ73ڷͥϹ˵иʱڸͻȻ̧
ֱץһҽı۰һ£ҽסڸɵĸ첲ܿŪˡ

һϺ󣬳½ܸ1.5Ԫ

Ȼ͸еͬȻڸɻûôΪ
ʲôҪأй£֪ٽǮΥ£
ΪʲôˡǱ򡱣أ

Ϊ˾˽ԴʵϵͬҽԺֲо
÷飬ʾϣܹɷýڡʾҪ
ʾڣüߵϢ˵ڶԼʱ䣬ȴҲӵ绰ˡ

Ǽִͨ˸ԭһ(200020067)ĵ绰
һǹֲרңͬʱҲǴķ
ͬڡȵ˶ԱֵСʮֲ׵ġΪ½
ΪΪжı׼ǰմͳȫֹͣ
ֹͣȵĻǶԹԴļ˷ѣҲժٵá
ؤһʱһѲٵһְûܵκǣǾ
֪ʿ͸¶һڼ䣬Դȡ涨˳棬
Ƿȡٵ

Ϊ֤һ㣬ϣ½ܹһصǳһ
ʾܽܲɷãϷ細Ѿϸʵû漰
Ҳ͸¶ҪɷãݽʽĲɷ룬λоܾ
ܽܲɷãЩʣЩʡɼԴ
УеĹԱ©

й̷ֲݼ˽ַǳǷ
ԴȡеĽǮףҲ人ͬҽԺֲڣ
ʵڹƻҲˣƺѾγһǱ򡱣Ȼ
֪ΥΥʣȴûȥ

йһֱܹϵȨ֯ͳƣ99%ϵ
̷ֲ1%̷ٵĴϣй
͹涨̷ʬ崦ȨУκ˲ժȡ˵٣
Ǿ嵽ִУǱ򡱻ҽѧٵ󣬸
ġǹְҵ£ǶȨĻ
أؽĽ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

Ȱ֢壬ʦ֧ͬԮĹ

ɽϴ 

ձйȾ⣬߻Ըⷭ룬ע⡣

ձ ߣ֯2007727գ

    Ⱦصй;ø߶ȳɳڡ1ձһѾ
滯еطѹ˾ĲһЩĵ(й)ʦǿʼ
ǶԹϵһձ˸ǴǿԮǲμӹ
ˮٶ2ȹϵձʦ򻯹ҵ԰ֳ֢
ʦڹͬŬ

    бºӡʵƮŶѪɫˮйý屨˺ˮ
Ⱦ֮󣬵طæӸ֮Ѫɫԭ
Ϊܱߵŷŵˮ1998Ұձҵڵ180ͿϡȾϡ
ũҩСģҵڴˣȻ100ҵĹ

    ͬڸζϸӡֺɫͶѹղķ
ȾơҵͣձȪϵơ......
ǰֳ۲ձʦϻţųԭʦԱ12ˣӺĳԱ
ǶȾس̶Ⱦ㵲ѡ

    ˵Ⱦصǣбͷ壨˿13000Լ
200֢3֢ȫƽ25йڶ׳ơ֢塱е
һܹҵˮȾĵˮгıӡﱻΪ²ԭ

    2001͹Ǩƺ⳥⿪ʼһܾϷã
ɧɱвĹ֧ԮNGO֯Ⱦ֧ܺԮ
ạ̃У֣־Ը-ʦԺϣԺܾ

    ʦ˵ǰ13ʵص飬ֹһε⵽͵ĺԱŹ
о尲ȫ⡣԰Ǵ˵Ҫ˰ԴϲĹ
лкĿӰжϡ

    100˵ԭҲѹֻʣ11ˡ

    ˵ֳԭ֮һ----35 ꣩Ķӣ4꣩5µʱ
ϰ߲ˮĻѧȾ²ԭ

    ΪβݽǮڲûпáҾԲˮ
ȥ˵

    2004԰ȥ37꣩Ҳ˵20 3ο­
5벡ħûоȵӡʲôûˡԭ
ֻʣ1ˣҲҪס

    ״Ҫ7ұ湤⳥11ԭ棨ʧȣ150ԪǨƹ
Ⱦģˮȡ÷Ժ״ܴӮ˾أ
ʦ˵ǽμӹˮٶкʹ4ȹϵձʦľ
ͽ顣

    μʵӲĴѷʦձʦϻṫԲ߻ȫίԱίԱ
Ⱦϡ5ʹȪϵʯ޹⳥ϡ6
ŷḻϾ顣ѷʦ˵ձĹҲܵεѹ
7вۡձľ޷ֱй֧ԭ棬Ѱ֧Ԯ
ܽۺ϶ԲߵȾ黹ЧġǽйԭʦһŬ

    ạ̃УйѧӷΪ1998ڱز
ŵȺʽӪӵ300ҵоԱ־ԸʦȫԵķ
֯ĿǰΪֹ֧Ԯ89ϣʤ߻ʵԺͽķʽʤ
ǻʤȫǾʧϣνİ֢ϣԼȾĽ⳥ϵȫ
ٷԺѡ

    2001ձ֮ạ̃УֺͣձʦϻṫԲ߱ȫίԱ
ῪʼձʦϻṫԲ߱ȫίԱܣạ̃УĴη
ȻȨ϶ԭΪųμӹˮٶϵľḻ
ʦΪûųԱ

ע

1ձ195670ƽGDPά15%ңͬʱ๫
⡣

21950꣬ձܱˮٶ½ѵèòèǣ
衣1956꿪ʼˮٶԭļ״Ϊƽϰ
֪𺦡ͷʹ˶ʧ̥ΡεȣΣ߶
ܱѧҽѧԺо֤ʵλˮٶеձطϹ˾ŷŵĶ׻
ˮȾˮͱȾܱˮٶΪˮĴʶ硣
кҲֹͬĲΪڶˮٶ

3ԡ򣬱֢ΪؼʼԷഥĿĵҳ

4ձкˮؽȾȫرǹͷʹ
ʧȥͶ

5ձٹ·ͨ񻧣߾ظձ
ٹ·˾ҪβȾ1998Ժͽȫʤߡʦ
Ҫһɫա

6ʯһּص°ʣ۳ڣ°䡣ŦԼůܵ
ʯΪ²㣩ըҪ·ըֳ·£װ


7һʼˮٶĲ򲢲оԱձع˾ŷŵˮ
²Ŀԭ֮󣬻ܵȶ෽ѹˮٶкܶȾ
Դ----ձع˾ձع˾Ҳ˻˲ͬ顣ںԭ
Եʱ򣬾ܲΧձع˾ձΪ
й֮ͬ1969껼߼Ժϣྭۣ
1973䶨ڻ߾϶ÿ˿Ի1600-1800Ԫۺ
Լ100ң⳥鲻ͬ⳥вͬԼҽƲ

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)



2007-07-26й걨
 ǿ

    ԺӡȹһܸһظкϸСĹһ
գߵԺһ󰸡

    û뵽Ժ⡰šͦ򵥵ģݶʣֻҪһ
šԺڲ׼գΪȲ֪飬Я֣
ʱĴ

    죬4ڿͥСһشͨ°ֵǣ
ͥϳ˷١ˡ绤ʦ֮⣬ȴûڵϾġ
šֹ۲3ͥҲŵӰӡ

    ƶȣƶȵĶ֮ҲǺйĲ֮ͬ
ҪΪ˿󰸲ģţЩʧǣҵԺ
鴦ѯʣһλŮʿңŲǱҪģֻڱҪ²
ʱ齨ΪɣȨѡɷٶϰ


     鴦ṩϢѡһŵȥҷַ
ͥİϴβͬͥ߰ڷ4ӣϯĵһҲ
סšԤλֽˡ绤ʦͱ
ͥұߣмߴǴɫ۵з٣ֱ
졣űװλŮԱڷٵһ㡣ͥΧ
4λά

    ԱȫֻһȺźƵŶɷ뷨ͥҿ
ĺǡ4040ϯλǰվ֣Ա
Чҷɡ

    ϸ40ˣʹϿȺûɶаˣҲкˣ
һ˵ףŴС

    Щº󣬷ٿʼǷǸлʱ
з񡣡Ժм佫12˱ѡųԱǵ
ξȡر˫֤ݺ󣬾Ƿ

    ţټ򵥽˱췽ָر20061221ĳ
·Ʒֵ500Ԫϣڱץй4
һףߴ򱣰

    ֮󷨹źѡһ⣬Ҫ˾ʾⲢ
͡û˲񣿡˾֡

    û21£˾֡

    

    ûʶˣָָڱ绤ʦԱߵʡ
3ŵİŮӻش𣬡Һļѡ

    ûʶλ绤ʦһһŮش˵ʶΪ֮ǰί


    û˾Լʤεģһλͽϴ˵Ҳɣ
Ҳϸ񡱡

    ʾ绤ʦмûѧУͥ
Űʦʡ

    ơ37ӱʾСʱ򱻼̸Ű

    ûֺԴˣ8˾ʾ⡣

    ӰԱж𣿡3˱ʾӰ죬5˱ʾ
Ӱ졣

    ֵźѡˡ

    û˵ļΣ3˱ʾС

    û˾з򷴾򣿡˻ش

    ʽźѡȫͥͥڼ䣬١ʦ
̶ͬųԱǰѸΪʵĺųֱ
ʣ12ܽܵѡ

    Χ12ųԱٴν뷨ͥȾģȻ¡
ʱҿ˿ͥϵıӣѽӽ11ʱ30֡Ҳ˵ѡųԱͻ
˽Сʱ

    ʽ󰸿ʼ֤˵ͥһλŮ֤ϯб
Աĳ̳ľ绤ʦ͹ȺߵĸǰͰ
ʻųԱֻע⿴¼Ҳܽ
ͷӶ

    12ʱͥ˵ųԱԻؼҳԷ1ʱ15
ͥڼųԱ໥ۣҲܺͱ绤ʦӴ

     ͥʱҽ˽ƶȡǸң40źѡ
Ǵӱѡѡģѡеĺѡ˱μӣΪ
ǹ񣬶ұѡڵĵλͬ١ձѡе
Աˣÿ취Ժÿ˲21Ԫûбѡϵÿ˲8Ԫ
Ϊͨѡ

    ڷͥУеǷܹҽⱻѡУ

    Ÿ˵˵º˵ѣ˽
ɡ

    12˻ؼҳԷڼ䣬α֤ǲ໥ۣǷܷ
˵

    ǲ໥ۣҲϣô˼
ʦǽӴط£˫ָء

    磬ҲؼҳԷɷиѴ绰ҰæӦ3࣬
ºϵԺͥѿһˡ

    ҼæԺ鴦ͥһλȡһļеݸң
ǱԼɣ

    һѷ飬ҿȷѡ磬ͥϷԱ仯
˵ͥͲˡҵ£λ
˼򵥽ͥдͽ6¡

(XYS20070728)

˿(www.xys.org)(xys.dxiong.com)(xys.freedns.us)(xys-reader.org)

һΪ˰޷˿վĹ˽˿վĶ̬ؿ
˿ʼбxys@yahoogroups.com

ʼбÿ췢һ˿վ¸µϣÿµ׷һÿ
Ŀ¼ʼбĶμ롰˿֮ѡ
ʼбxys_friends@yahoogroups.com

ù䶩ġù䣬ܿ޷յ
Ƽ䣺yahoo.com, hotmail.com, gmail.com

ġ˿ʼбĵ䷢һհż

xys-subscribe@yahoogroups.com 

塢ͣ˿ʼбͣ䷢һհż

xys-unsubscribe@yahoogroups.com 

Ͷxinyusi@yahoo.comôıļͶ塣

˿(www.xys.org)(xys.dxiong.com)(xys.3322.org)(xys.xlogit.com)
